Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOakley Regulatory News (OCI)

Share Price Information for Oakley (OCI)

Share Price is delayed by 15 minutes
Get Live Data
516.00    2.00 (0.39%)
Bid:
514.00
Ask:
518.00
Spread: 4.00 (0.778%)
Market Cap: £853.03m
OCI Live PriceLast checked at - London Stock Exchange

Intraday Oakley Share Chart

Results analysis from Kepler Trust Intelligence

11 Mar 2022 09:08

RNS Number : 4996E
Oakley Capital Investments Limited
11 March 2022
 

Oakley Capital Investments (OCI)

11/03/2022

 

Results analysis from Kepler Trust Intelligence

Oakley Capital Investments (OCI) announced its final results for the year ended 31 December 2021, in which strong earnings and realisations drove significant NAV growth of 35% on a total return basis, and a share price total return of 48%.

76% of the increase in the portfolio's value was driven by earnings growth, with underlying investments maintaining their pattern of strong growth. Average EBITDA growth over the year was 28%, underpinned by digitally enabled businesses and recurring revenues.

Oakley Fund commitments at the year-end were £404m, increasing to £740m when including the initial commitment to Fund V announced post year-end. The Chairman states that "With…a rich pipeline in place, OCI has the resources to help finance new Fund investments in the coming years, using balance sheet cash as well as proceeds from anticipated future realisations".

 

Kepler View

Oakley Capital Investments (OCI) offers a concentrated, but unique exposure to a number of very interesting growth companies. Certainly, the world has changed markedly from the year end date, but the underlying themes which have driven such strong earnings growth over the last year, seem unlikely to be derailed. At the year end, the portfolio exposure to consumer companies lay at 44%, with the rest of the portfolio relatively evenly balanced between technology and education.

When compared to the LPE peer group, OCI is relatively highly committed as a proportion of NAV. However, on the same day as the results announcement, the board announced they had authorised a buyback programme up to an aggregate consideration of £20 million, potentially an indication of the value they see in the shares (currently at a c. 30% discount to NAV), and their confidence on their balance sheet position.

Oakley Capital's focus on active management and value creation has helped its tech-enabled portfolio to continue generating strong earnings growth. Its unique deal sourcing network means they are able to find promising investments at attractive valuations. In the current period of geopolitical, market and economic volatility, we share the board's confidence in Oakley's "capabilities as a leading private equity investor, as well as the long-term potential of the Oakley Funds, to continue generating superior returns for investors" which have delivered a five-year compound annual growth rate of 19%.

OCI's shares have de-rated with the market this year, and now trade at a discount to the 31/12/2021 NAV of c. 30%. One change this year is the move to quarterly NAV announcements, the first of which is expected to be announced on 27 April 2022 (for the NAV as at 31/03/2022)…

CLICK HERE TO READ THE FULL REPORT

 

Visit http://www.trustintelligence.co.uk/investor for more high quality independent investment trust research.

 

Important information

This report has been issued by Kepler Partners LLP. The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 70 Conduit Street, London W1S 2GF with registered number OC334771.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGCGDXXGBDGDB
Date   Source Headline
10th Feb 20217:00 amRNSDirector Dealing
29th Jan 20214:42 pmRNSDirector Dealing
27th Jan 20215:06 pmRNSDirector Dealing
27th Jan 20217:00 amRNSTrading update for the year ended 31 December 2020
26th Jan 20217:00 amRNSInvestment in idealista
7th Jan 20217:00 amRNSSale of the DWS division of the Daisy Group
22nd Dec 20204:11 pmRNSHolding(s) in Company
11th Dec 20202:33 pmRNSDirector Declaration
4th Dec 20203:58 pmRNSHolding(s) in Company
3rd Dec 20204:50 pmEQSHardman & Co Research: Oakley Capital Investments (OCI): NAV: conservative, robust and with growth upside
3rd Dec 20201:52 pmRNSTransaction in Own Shares
25th Nov 20207:00 amRNSHolding(s) in Company
23rd Oct 20207:00 amRNSDirector/PDMR Shareholding
22nd Oct 20207:00 amRNSAcquisition of WindStar Medical
6th Oct 202012:42 pmRNSHolding(s) in Company
6th Oct 20207:00 amRNSTransaction in Own Shares (Amendment)
2nd Oct 20204:33 pmRNSTransaction in Own Shares
2nd Oct 20207:00 amRNSShare Buy-Back Programme
1st Oct 20207:00 amRNSAcquisition of 7NXT
30th Sep 20201:54 pmRNSAppointment of Non-Executive Director
17th Sep 20207:00 amRNSOakley sells Casa.it to EQT
10th Sep 20207:00 amRNSResults for the six months ended 30 June 2020
1st Sep 20207:20 amEQSHardman & Co Research: Oakley Capital Investments (OCI) - initiation of coverage: 'When it rains gold, put out the bucket'
4th Aug 20203:09 pmRNSHolding(s) in Company
29th Jul 20206:15 pmRNSTransaction in Own Shares
29th Jul 20207:00 amRNSTrading update for the six months ended 30 June 20
15th Jul 20209:30 amRNSKepler Trust Intelligence: New Research
6th Jul 20207:00 amRNSCapital Commitment
30th Jun 20207:00 amRNSDirectorate Change
24th Jun 20206:02 pmRNSDirector Dealing
22nd Jun 202012:22 pmRNSHolding(s) in Company
19th Jun 20205:38 pmRNSDirector Dealing
19th Jun 20207:01 amRNSDirector Dealing
19th Jun 20207:00 amRNSDirector Dealing
18th Jun 20205:57 pmRNSHolding(s) in Company
18th Jun 20204:42 pmRNSTransaction in Own Shares
18th Jun 20207:00 amRNSShare Buy-Back
1st Jun 20202:25 pmRNSDirector Declaration
27th May 20205:01 pmRNSHolding(s) in Company
27th May 20207:00 amRNSResult of Annual General Meeting
22nd May 20204:33 pmRNSTime Out equity fundraise and OCI loan repayment
19th May 20207:00 amRNSDirector Declaration
7th May 20207:00 amRNSDirectorate Change and Total Voting Rights
1st May 20207:00 amRNSNotice of Annual General Meeting
8th Apr 20207:00 amRNSOakley completes sale of investment in Inspired
25th Mar 20207:00 amRNSCOVID-19 Update
20th Mar 20207:00 amRNSAnnual Report and Accounts 2019
18th Mar 20204:22 pmRNSTransaction in own Shares
18th Mar 20207:00 amRNSShare Buy-Back
17th Mar 20204:42 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.